Best Weight Loss Pills for 2026? FDA Approves First Oral GLP-1 as Patients Evaluate Wegovy, Zepbound, and Telehealth Access Pathways
Newark, DE, Dec. 29, 2025 (GLOBE NEWSWIRE) -- The term "best" reflects…
Best TRT Injection for 2026: Fridays Lists Prescription Testosterone in Injectable and Oral Formats as Men Compare Telehealth Hormone Options
IRVINE, Dec. 27, 2025 (GLOBE NEWSWIRE) -- Disclaimer: This article is for…
Is SynergyRx GLP-1 Legitimate? Platform Lists Compounded Semaglutide at $200 With Oral Tablet Options
SAN DIEGO, Dec. 26, 2025 (GLOBE NEWSWIRE) -- As the post-holiday period…
Best BPC-157 Oral Supplements: ProHealth’s Triple-Tested Formula Examined as Peptide Quality Verification Becomes Consumer Priority Heading Into 2026
CARPINTERIA, Dec. 23, 2025 (GLOBE NEWSWIRE) -- This article contains affiliate links.…
Quetzal Therapeutics Launches Phase III Clinical Trial of Oral QTX-2101 for Acute Promyelocytic Leukemia (APL)
CHICAGO, Dec. 02, 2025 (GLOBE NEWSWIRE) -- Quetzal Therapeutics, a biopharmaceutical company…
Alzheimer’s Association Statement on Oral Semaglutide Phase 3 Topline Data Release
- Results Underscore Need for Continued Research and Diverse Treatment PipelineCHICAGO, Nov.…
COLGATE DEBUTS FIRST-EVER VISIBLE WHITE PURPLE SERUM: A GAME-CHANGER IN ORAL BEAUTY
MUMBAI, India, Nov. 18, 2025 /PRNewswire/ -- Teeth may not always be…
Quanta Therapeutics Presents Positive Phase 1 Data for QTX3034, an Oral G12D-Preferring Multi-KRAS Inhibitor, in Patients with Advanced Solid Tumors
– QTX3034 monotherapy and the QTX3034-cetuximab combination demonstrated favorable safety profiles and…
PIVOT-PO Phase 3 Data Show Tebipenem HBrs Potential as the First Oral Carbapenem Antibiotic for Patients with Complicated Urinary Tract Infections (cUTIs)
Data presented at IDWeek 2025 after study stopped early for efficacyPrimary endpoint…
Merus Announces Petosemtamab in Metastatic Colorectal Cancer Abstract Selected for Plenary Session Oral Presentation at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
- Plenary session oral presentation: Friday, October 24 10:00 -11:40 a.m. ET…
